These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Perspectives on chemistry and therapeutic applications of Locked Nucleic Acid (LNA). Kaur H; Babu BR; Maiti S Chem Rev; 2007 Nov; 107(11):4672-97. PubMed ID: 17944519 [No Abstract] [Full Text] [Related]
8. Therapeutic Oligonucleotides: State of the Art. Smith CIE; Zain R Annu Rev Pharmacol Toxicol; 2019 Jan; 59():605-630. PubMed ID: 30285540 [TBL] [Abstract][Full Text] [Related]
10. Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development. Orum H; Wengel J Curr Opin Mol Ther; 2001 Jun; 3(3):239-43. PubMed ID: 11497347 [TBL] [Abstract][Full Text] [Related]
11. Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals. Campbell MA; Wengel J Chem Soc Rev; 2011 Dec; 40(12):5680-9. PubMed ID: 21556437 [TBL] [Abstract][Full Text] [Related]
12. Polyamine-oligonucleotide conjugates: a promising direction for nucleic acid tools and therapeutics. Menzi M; Lightfoot HL; Hall J Future Med Chem; 2015; 7(13):1733-49. PubMed ID: 26424049 [TBL] [Abstract][Full Text] [Related]
16. Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and phosphorothioate locked nucleic acid (LNA)/2'-O-methyl (OMe) mixmer anti-miRs in the absence of transfection agents. Torres AG; Threlfall RN; Gait MJ Artif DNA PNA XNA; 2011; 2(3):71-8. PubMed ID: 22567190 [TBL] [Abstract][Full Text] [Related]
17. Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4'-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer. Fluiter K; Mook OR; Vreijling J; Langkjaer N; Højland T; Wengel J; Baas F Mol Biosyst; 2009 Aug; 5(8):838-43. PubMed ID: 19603119 [TBL] [Abstract][Full Text] [Related]